MERSANA THERAPEUTICS INC. - COMMON STOCK

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2024 16:30:28 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

28 Feb 2024 07:00:08 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

27 Feb 2024 08:01:15 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

21 Feb 2024 08:00:22 By Nasdaq GlobeNewswire

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

01 Feb 2024 08:00:46 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

05 Jan 2024 08:01:19 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 16:30:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

07 Nov 2023 07:00:55 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

31 Oct 2023 16:30:25 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

31 Oct 2023 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Changes in Leadership

06 Sep 2023 07:00:40 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

08 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2023 16:05:52 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

27 Jul 2023 07:06:23 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

15 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

09 May 2023 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 May 2023 16:05:01 By Nasdaq GlobeNewswire